Tirzepatide 10mg
Tirzepatide in an injection pen. Dual GLP-1 and GIP agonist for demanding research.
Choose a variant
This product is intended exclusively for laboratory and research purposes. Not intended for direct use or human consumption. For persons over 18 years of age only.
About the product
Tirzepatide is a dual agonist of the GLP-1 and GIP receptors, delivered as a premium injection pen. An innovative molecule for metabolic syndrome research.
Each pen contains 10 mg of substance with purity ≥ 99% verified by HPLC analysis. The precise dosing mechanism ensures reproducible results.
Composition & specifications
The information below is for reference only and is intended exclusively for research purposes. It is not medical advice.
In clinical research, the starting dose was 2.5 mg once weekly subcutaneously.
Increase to 5 mg weekly after 4 weeks of tolerance.
Clinically tested doses of 5–15 mg weekly. Always follow the approved protocol.
Subcutaneous injection; rotate the injection site.
Upon receiving the shipment, place the product in a refrigerator immediately (2–8 °C). Do not freeze.
Protect from direct sunlight and heat sources. Keep in the original sealed packaging.
When stored correctly, the product is stable for the period indicated on the packaging. Use according to batch specification after opening.
What is a dual GLP-1/GIP agonist?
How should the pen be stored after opening?
Other products
